Autoantibodies in COVID-19 correlate with anti-viral humoral responses and distinct immune signatures

Patrick Taeschler[1†], MMed; Carlo Cervia[1†], MD; Yves Zurbuchen[1], MMed; Sara Hasler[1]; Christian Pou[2], PhD; Ziyang Tan[2], MSc; Sarah Adamo[1], MMed; Miro E. Raeber[1], PhD; Esther Bächli[3], MD; Alain Rudiger[4], MD; Melina Stüssi-Helbling[5], MD; Lars C. Huber[5], MD; Petter Brodin[2,6,7], MD, PhD; Jakob Nilsson[1], MD, PhD; Elsbeth Probst-Müller[1], MD, PhD; and Onur Boyman[1,8] *, MD

[1] Department of Immunology, University Hospital Zurich, Zurich, Switzerland

[2] Science for Life Laboratory, Department of Women's and Children's Health, Karolinska Institutet, Solna, Sweden

[3] Clinic for Internal Medicine, Hirslanden Klinik St. Anna, Lucerne, Switzerland

[4] Department of Medicine, Limmattal Hospital, Schlieren, Switzerland

[5] Clinic for Internal Medicine, City Hospital Triemli Zurich, Zurich, Switzerland

[6] Pediatric Rheumatology, Karolinska University Hospital, Solna, Sweden

[7] Department of Immunology and Inflammation, Imperial College London, London, United Kingdom

[8] Faculty of Medicine, University of Zurich, Zurich, Switzerland

[†] Contributed equally

* Corresponding author: Onur Boyman, MD, Department of Immunology, University Hospital

Zurich, Schmelzbergstrasse 26, 8091 Zurich, Switzerland. E-mail: onur.boyman@uzh.ch;

phone: +41 44 255 2069.

This work was funded by Swiss National Science Foundation grants 310030-172978 and

310030-200669 (to OB), 4078P0-198431 (to OB and JN) and NRP78 Implementation

Programme (to CC and OB), Digitalization Initiative of the Zurich Higher Education

Institutions Rapid-Action Call #2021.1_RAC_ID_34 (to CC), Swiss Academy of Medical

Sciences grants 323530-191220 (to CC), 323530-191230 (to YZ) and 323530-177975 (to SA),

Forschungskredit Candoc of University of Zurich FK-20-022 (to SA), Young Talents in

Clinical Research Project Grant (YTCR 08/20) by the Swiss Academy of Medical Sciences

and Bangerter Foundation (to MER), the Clinical Research Priority Program of University of

Zurich for CRPP CYTIMM-Z (to OB), the Pandemic Fund of University of Zurich (to OB),

and an Innovation Grant of University Hospital Zurich (to OB).

The authors declare no competing financial interests.

Abstract

Background

Several autoimmune features occur during coronavirus disease 2019 (COVID-19), with possible implications for disease course, immunity, and autoimmune pathology.

Objective

We longitudinally screened for clinically relevant systemic autoantibodies to assess their prevalence, temporal trajectory, and association with immunity, comorbidities, and severity of COVID-19.

Methods

We performed highly sensitive indirect immunofluorescence assays to detect anti-nuclear antibodies (ANA) and anti-neutrophil cytoplasmic antibodies (ANCA), along with serum proteomics and virome-wide serological profiling in a multicentric cohort of 175 COVID-19 patients followed-up to one year after infection, eleven vaccinated individuals, and 41 unexposed controls.

Results

Compared to healthy controls, similar prevalence and patterns of ANA were present in patients during acute COVID-19 and recovery. However, paired analysis revealed a subgroup of patients with transient presence of certain ANA patterns during acute COVID-19. Furthermore, patients with severe COVID-19 exhibited a high prevalence of ANCA during acute disease. These autoantibodies were quantitatively associated with higher SARS-CoV-2-specific antibody titers in COVID-19 patients and in vaccinated individuals, thus linking autoantibody production to increased antigen-specific humoral responses. Notably, the qualitative breadth of antibodies cross-reactive with other coronaviruses was comparable in ANA-positive and ANA-

negative individuals during acute COVID-19. In autoantibody-positive patients,

multiparametric characterization demonstrated an inflammatory signature during acute

COVID-19 and alterations of the B cell compartment after recovery.

Conclusion

Highly sensitive indirect immunofluorescence assays revealed transient autoantibody

production during acute SARS-CoV-2 infection, while the presence of autoantibodies in

COVID-19 patients correlated with increased anti-viral humoral immune responses and

inflammatory immune signatures.

Word count: 243

Max word count: 250

Key messages

- Acute COVID-19 patients exhibit transient autoantibody production, indicating a
temporary loss of self-tolerance.

- In COVID-19 patients, the presence of autoantibodies is associated with increased
anti-viral humoral immune responses and inflammatory immune signatures that
persist into recovery.

Capsule Summary

Autoantibodies in COVID-19 patients are transient and correlate with increased anti-viral
humoral immune responses and an inflammatory immune signature persisting into recovery.

Keywords

SARS-CoV-2, COVID-19, COVID-19 vaccination, Anti-nuclear antibodies, Anti-neutrophil
cytoplasmic antibodies, Autoimmunity, Autoantibodies, VirScan

Abbrevations

AC – anti-cell

ANA – anti-nuclear antibody

ANCA – anti-neutrophil cytoplasmic antibody

COVID-19 – coronavirus disease 2019

IIF – indirect immunofluorescence

SARS-CoV-2 – severe acute respiratory syndrome coronavirus 2

Introduction

Acute coronavirus disease 19 (COVID-19) causes a large clinical spectrum, ranging from a mild condition in the majority of cases to fatal disease in 1-2% of subjects (1-3). Several features of acute COVID-19 resemble clinical manifestations of systemic inflammatory and autoimmune diseases, such as fatigue, myalgia, hyperinflammation, thrombosis, and skin rashes (3, 4). Furthermore, COVID-19 may trigger the onset of autoimmune pathology, as reported for Guillain-Barré syndrome, anti-phospholipid syndrome, vasculitis, and multisystem inflammatory syndrome in children (5-9). *Vice versa*, autoimmune phenomena have been connected to the pathogenesis of severe COVID-19. Pre-existing autoantibodies targeting the type I interferon pathway have been found in about 10% of COVID-19 cases with critical disease (10-12).

Other acute or chronic viral infections have been associated with autoimmune responses, which have been proposed to arise by molecular mimicry, epitope spreading or bystander activation (13). Various autoantibodies have been described in association with COVID-19, including anti-nuclear antibodies (ANA) (14-20), anti-neutrophil cytoplasmic antibodies (ANCA) (15, 16, 21), anti-phospholipid antibodies (5, 8, 14, 17, 19, 22), and antibodies targeting different extracellular antigens (11, 16). While the presence of different autoantibodies has been associated with severe COVID-19 and worse outcome (11, 15, 17-19), it remains unclear to what extent autoantibodies are triggered by acute infection, even though transient autoreactivity and new development of autoantibodies have been suggested in a subgroup of COVID-19 patients (16, 20). Furthermore, several aspects of autoantibodies in COVID-19, including their interplay with virus-specific humoral responses and their durability after acute infection, need further elucidation. In this study, we comprehensively characterized autoantibodies by using highly sensitive indirect immunofluorescence (IIF) assays in a multicentric prospective cohort of 227 individuals.

Methods

Human subjects and patient characteristics

Following written informed consent, adult individuals were recruited for medical history and blood sampling between April 2020 and May 2021. The study was approved by the Cantonal Ethics Committee of Zurich (BASEC #2016-01440). The cohort comprised mild and severe COVID-19 patients, healthy controls, and vaccinated individuals.

COVID-19 patients (**Table 1**, **Table S1**)*:* 175 patients with reverse transcriptase quantitative polymerase chain reaction (RT-qPCR)-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection were included during acute COVID-19 at four hospitals in the Canton of Zurich, Switzerland. COVID-19 was classified for maximum disease severity according to the World Health Organization (WHO) classification criteria into mild disease – including asymptomatic (n = 4), mild illness (n = 93) and mild pneumonia (n = 12) – and severe disease – including severe pneumonia (n = 30) and acute respiratory distress syndrome (ARDS; n = 36) (23). Follow-up visits for medical history and blood collection were conducted approximately six months and one year after symptom onset. Unreachable individuals or those declining further participation were lost to follow-up.

Healthy controls (**Table 1**)*:* 41 participants with negative history of SARS-CoV-2 infection and serology were recruited. Five individuals developed COVID-19 after inclusion and were subsequently allocated to the patient cohort.

Vaccinated individuals (**Table S2**)*:* 11 individuals with a negative history and serology for SARS-CoV-2 infection were sampled once before vaccination, once after the first and twice after the second mRNA vaccination with BNT162b2 (BioNTech-Pfizer).

Autoantibody detection

ANA were measured by IIF on HEp-2 cells (Euroimmun) with a cut-off dilution of 1:320.

ANCA were measured by IIF on neutrophils fixed by ethanol and formalin (Euroimmun) with

a cut-off dilution of 1:40. IIF imaging was performed using a diagnostic, computer-aided

microscopy system (Euroimmun). ANA patterns were classified according to the international

consensus on ANA patterns anti-cell (AC) nomenclature (24) by blinded trained personnel. For

paired analyses of ANA patterns, 129 pairs of IIF pictures at 1:320 dilution were blinded for

patient characteristics and sampling timepoint, and examined pairwise by the same observer.

Antibodies against myeloperoxidase and proteinase 3 were measured on Phadia^{TM} 250

(ThermoFisher Scientific) or on Bioflash® (Werfen) according to manufacturer's instructions.

Immunoassays

Immunoassays for immunoglobulin (Ig) subsets, anti-SARS-CoV-2 spike S1-specific IgA and

IgG, interleukin (IL)-1β, IL-2, IL-5, IL-6, IL-10, IL-12, interferon-γ (IFN-γ), soluble IL-2

receptor α (sIL-2Rα), and tumor necrosis factor α (TNF-α), were performed in accredited

laboratories at University Hospital Zurich. Serum Ig subsets were quantified on an Optilite®

turbidimeter (The Binding Site Group). S1-specific IgA and IgG were measured by enzyme-

linked immunosorbent assays (ELISA) (Euroimmun), as established (25). IL-1β, IL-2, IL-6,

IFN-γ and sIL-2Rα were determined by ELISA (R&D Systems) on Opsys Reader^{TM} (Dynex).

IL-5, IL-10 and IL-12 were measured by cytometric bead assays (BD Biosciences) on a Navios

cytometer (Beckman Coulter). TNF-α was determined with a kit (R&D Systems) using

MagPix® (ThermoFisher Scientific).

Flow cytometry

As established (26), blood samples were processed and analyzed in accredited laboratories at

University Hospital Zurich. Blood samples were lysed with VersaLyse, fixed with IOTest3

solution and stained with antibodies (Beckman Coulter; **Table S3**). Absolute cell counts were

determined using Flow Set Pro Fluorospheres calibration beads on Navios (Beckman Coulter).

Serum proteomics

Serum samples were analyzed by a proximity extension assay-based technology 92-plex

inflammation panel (Olink®), as established (26-28). Six parameters were excluded because

less than 50% of samples showed results above detection limit.

Human virome-wide serological profiling

As established (7, 29), serum samples were inactivated, normalized for total IgG concentration,

and incubated as duplicates with a bacteriophage library displaying linear, 56 amino acid long

viral epitopes. IgG-phage complexes were captured with magnetic beads, lysed and quantified

by next-generation sequencing. Blank beads samples were used as negative controls. Reads

were mapped to the epitope library with Bowtie2, and counts were obtained using SAMtools.

A previously described binning strategy was used to identify positivity for epitopes ((30)), with

a minimum z-score of 3.5 for both sample replicates compared to negative controls. Results for

a total of 112 different human viruses were included in the further analysis. (**Table S4**),

whereas eukaryotes, prokaryotes, non-human viruses and human viruses with no variance or a

maximal summed epitope hit count below three were excluded.

Statistics

Statistical analyses were performed using R (version 4.1.0). Unless otherwise specified,

between-group comparison was performed using two-tailed, non-parametric, unpaired testing

(Mann-Whitney U) for numeric variables and odds ratios with Fisher's exact test for categorical

variables, with p-values of <0.05 defined as significant. Missing values were omitted. Principal

component analyses (PCA) were performed using stats (4.2.0) and factoextra (1.0.7) with

scaled, centered variables, and loadings are shown as variable coordinates. Spearman's rank

correlation was used for associations of numeric variables. Pairwise protein alignment for 56-

amino acid (AA) long peptides with SARS-CoV-2 spike (Uniprot Entry P0DTC2) and

nucleoprotein (P0DTC9) was generated using Biostrings (2.60.2), with BLOSUM62

substitution matrix and gap opening and extension penalty of -11 and -1, respectively. Data

visualization was performed using ggplot2 (version 3.3.5), ggfortify (0.4.12), ggVennDiagram

(1.1.4), UpSetR (1.4.0), and corrplot (0.90). Horizontal lines in violin plots represent medians.

Regression lines represent simple linear regression models.

Results

Presence of systemic autoantibodies during acute COVID-19 and recovery

We performed a comprehensive immunological characterization of 175 individuals with confirmed COVID-19 up to one year after infection (**Fig. 1A** and **Table 1, Table S1**), including autoantibody screening by IIF, serum proteomics and serological profiling. 41 individuals with negative history and serology for SARS-CoV-2 infection were included as controls (**Fig. 1A** and **Table 1**). Furthermore, eleven unexposed individuals were sampled before and after vaccination with BNT162b2 (**Table S2**).

Using a highly sensitive IIF screening assay, we detected titers of 1:320 and above in 17 of 41 (41.4%) healthy individuals thus testing positive for ANA (**Fig. 1B**). This prevalence of ANA positivity was similar to that in COVID-19 patients during acute disease (48.0%, odds ratio (OR) = 1.30, p = 0.49) as well as six months (47.4%, OR = 1.27, p = 0.59) and one year after recovery (42.3%, OR = 1.04, p = 1) (**Fig. 1C–E**). Most of the observed ANA titers were just above the positivity threshold of 1:320. Interestingly, we observed a trend of higher ANA prevalence in individuals with severe COVID-19 compared to mild disease during acute infection (OR 1.85, p = 0.061), which was significantly higher at six months after recovery (OR = 3.81, p = 0.0015) (**Fig. 1C** and **D**).

Similarly, we used an IIF assay to detect ANCA. ANCA prevalence was similar in mild COVID-19 patients during acute disease (3.6%) compared to healthy individuals (2.4%) (**Fig. 1F** and **G**). Conversely, we observed a significantly higher ANCA prevalence in severe acute COVID-19 patients (19.7%), both compared to healthy subjects (p = 0.0082) and mild COVID-19 cases (p = 0.0096) (**Fig. 1F** and **G**), which returned to ranges seen in healthy individuals after six months (5.1%, p = 0.61) and one year (14.3%, p = 0.15) (**Fig. 1H** and **I**).

In several patients, nuclear ANA, cytoplasmic ANA, or ANCA were detected concurrently, particularly during acute COVID-19 (**Fig. 1J–M**). Moreover, ANCA showed a tendency to be

more frequent in ANA-positive (14.3%) compared to ANA-negative (5.5%) individuals during

acute COVID-19 (p = 0.06) (**Fig. 1K**).

Characteristics of ANA and ANCA patterns in acute COVID-19

To gain a qualitative appreciation, we classified ANA patterns according to the international

consensus on ANA patterns anti-cell (AC) nomenclature (24). ANA patterns were very similar

in healthy controls and COVID-19 patients at all three sampling timepoints, and in some

participants different patterns were detected concurrently (**Fig. 2A–D, Fig. S1A–D**). The most

common nuclear patterns were fine-granular nuclear (AC-4 or AC-4 like) and nucleolar (AC-

8, AC-9, and AC-10), whereas the most common cytoplasmic patterns were speckled (AC-19

and AC-20) (**Fig. 2E–G**).

ANCA patterns observed during acute COVID-19 and follow-up were mostly cytoplasmic

(**Fig. 2H**). However, cytoplasmic patterns were atypical and, accordingly, none of the ANCA-

positive patients showed positivity for either anti-myeloperoxidase (MPO) or anti-proteinase 3

(PR3) antibodies (**Fig. 2I**), suggesting other antigen specificities than commonly found in

ANCA-associated vasculitis (31, 32).

Temporal trajectory of autoantibodies in individual COVID-19 patients

To appreciate changes in ANA and ANCA on an individual level, we performed paired analysis

of all patients that attended at least one follow-up (n = 116 at six months and n = 13 at one

year). For ANA, we observed similar proportions of patients with isolated ANA positivity

during acute disease (14.7%) and during follow-up (12.4%) (**Fig. 3A**). However, a trend toward

a higher proportion of new ANA development at follow-up visit was evident in patients with

severe COVID-19 (20.5%) compared to patients with mild COVID-19 (8.2%) (OR = 2.84, p =

0.054) (**Fig. 3B**). To also account for subtle changes of IIF patterns, we conducted a blinded,

paired analysis of IIF images to identify patterns that were transiently present either during

acute disease or follow-up. Strikingly, we found transient patterns in 11 of 62 (17.7%) ANA-

positive COVID-19 patients during acute disease, with speckled cytoplasmic (AC-19 and 20),

nucleolar (AC-8, 9, 10) and mitotic being the most frequent patterns (**Fig. 3C** and **D**). In stark

contrast, only three of 59 (5.1%) ANA-positive individuals presented with a pattern during

follow-up that was not present during acute disease, thus demonstrating that transient ANA

patterns were significantly more prevalent during acute COVID-19 (p = 0.045) (**Fig. 3C**).

For ANCA, we observed that of ten patients that tested positive during acute COVID-19, eight

were negative during follow-up, whereas only two remained positive (**Fig. 3E**). Furthermore,

only one patient newly exhibited positive ANCA at follow-up (**Fig. 3E** and **F**). Collectively,

we found that a subgroup of individuals shows ANA and atypical ANCA production during

the acute phase of COVID-19, which usually subsides during follow-up.

Virus-specific responses in autoantibody-positive and SARS-CoV-2-vaccinated subjects

To elucidate the influence of autoantibody production during acute infection, we investigated

the correlation of autoantibodies with specific humoral immune responses to SARS-CoV-2.

We longitudinally assessed SARS-CoV-2 spike 1 (S1)-specific immunoglobulin A (IgA) and

IgG titers and found that presence of ANA was associated with higher concentrations of S1-

specific antibodies in COVID-19 patients during acute disease, which extended to six months

after recovery (**Fig. 4A**). Conversely, one year after recovery, we did not observe any

differences (**Fig. S2**). The presence of ANA correlated significantly with S1-specific IgG levels

even after accounting for age, disease severity, and sampling timepoint in a multiple linear

regression model, which was not the case of S1-specific IgA (**Fig. 4B**, **Table S5**). Similarly,

we found higher S1-specific IgA and a trend toward higher IgG titers in patients that tested

positive for ANCA during acute disease (**Fig. 4C**).

To elucidate whether autoantibodies were associated with an increased humoral immune

response only after natural SARS-CoV-2 infection or also after other antigen-specific immune

responses, we measured ANA and S1-specific antibodies in 11 individuals before and after

COVID-19 vaccination with BNT162b2 (**Fig. 4D–F**, **Table S2**). Although a tendency of an

increased ANA prevalence following the first vaccine shot was apparent, no significant

difference was observed between sampling timepoints (**Fig. 4D**). We observed higher S1-

specific IgA in ANA-positive individuals when combining data from two and four weeks after

the first vaccine shot, whereas no difference was observed for IgG (**Fig. 4E** and **F**). In summary,

these findings suggest the presence of autoantibodies is associated with increased S1-specific

humoral responses following acute COVID-19 up to six months after recovery and following

SARS-CoV-2 vaccination.

Human virome-wide serological profiling in acute COVID-19

Next, we sought to investigate qualitative aspects of antibody responses during acute COVID-

19 with respect to previous anti-viral humoral responses in ANA-positive and ANA-negative

individuals. Based on the phage immunoprecipitation sequencing (PhIP-seq) technology

(VirScan) (33), we performed human virome-wide serological profiling in 97 acute COVID-

19 patients and 18 healthy controls. We assessed the results of antibodies directed to 112

different viruses (**Table S4**), with data for a total of 87,890 epitopes, consisting of 56-amino

acid (AA)-long, overlapping peptides. The library comprised all six human coronaviruses

(HCoV) described before the COVID-19 pandemic, including HCoV-HKU1, HCoV-NL63,

HCoV-229E, betacoronavirus 1 (BCoV1, including HCoV-OC43), severe acute respiratory

syndrome-related coronavirus (SARS-CoV), and Middle east respiratory syndrome-related

coronavirus (MERS-CoV).

A multivariate analysis using the summed epitope hits per viral species revealed distinct

differences in COVID-19 patients compared to healthy controls, which were particularly

pronounced more than one week after symptom onset (**Fig. 5A**). Between-group comparisons

of COVID-19 patients and healthy controls revealed a significant difference ($p < 0.005$) of

summed epitope hits for eight viral species (**Fig. 5B**). Of these, four enterovirus species were

more abundant in healthy controls. Conversely, antibodies targeting cytomegalovirus (CMV)

and Pegivirus A, and those directed to SARS-CoV and MERS-CoV were significantly more

abundant in COVID-19 patients, whereas antibodies targeting the four common coronaviruses

HCoV-HKU1, HCoV-NL63, HCoV-229E, and BCoV1, showed a parallel, but insignificant

trend ($p > 0.005$) (**Fig. 5B**). Antibodies directed to all coronavirus species correlated positively

with time from symptom onset (**Fig. 5C**), thus indicating production of cross-reactive

antibodies during acute COVID-19.

To further study antibodies targeting CoVs in acute COVID-19, we evaluated serological

profiles on a singular epitope level. We found a significantly higher ($p < 0.05$) proportion of

COVID-19 patients tested positive for a total of 18 CoV epitopes compared to healthy controls,

of which 16 were in the spike and two in the nucleoprotein (**Fig. 5D**, **Fig. S3A**). Since healthy

individuals tested negative for these but positive for only one epitope (**Fig. 5D** and **E**), we

hypothesized these 18 CoV epitopes enriched in COVID-19 patients were targeted by

antibodies newly produced during acute COVID-19 and cross-reactive with shared epitopes of

other CoVs. Pairwise protein alignment of these epitopes with corresponding SARS-CoV-2

proteins allowed identification of regions of SARS-CoV-2 spike and nucleoprotein targeted by

cross-reactive antibodies, comprising two segments (AA positions 777–886 and 1105–1195)

of spike S2 domain and one segment of nucleoprotein (AA 140–252), which have been

previously identified in COVID-19 patients (34). Patients with severe COVID-19 tested

positive for significantly more cross-reactive antibodies than mild disease patients (**Fig. 5E**).

However, no significant difference was observed in ANA-positive compared to ANA-negative

patients (**Fig. 5F**), although the proportion of ANA-positive patients that tested positive was

slightly higher for most cross-reactive epitopes (**Fig. 5G**).

To explore potential correlations of ANA with humoral responses against other viruses, we

compared seroreactivity against all tested viral epitopes and ANA positivity. Several epitopes

were detected more frequently ($p < 0.005$) in ANA-positive, but not in ANA-negative,

individuals (**Fig. 5H**). Three of the identified peptides were located on Epstein-Barr virus

(EBV) nuclear antigen 2 (EBNA-2), to which ANA-positive participants showed more epitope

hits, independent of age (**Fig. S3B**). When combining data of all available epitopes, we found

significantly more hits in ANA-positive compared to ANA-negative participants, which was

most pronounced at younger age (**Fig. 5I**). Thus, human virome-wide serological profiling in

acute COVID-19 revealed antibodies cross-reactive to other coronaviruses, whereas ANA-

positive participants producing antibodies to more viral epitopes on a virome wide level.

Association of autoantibodies with inflammatory signature during acute COVID-19

Several studies have associated autoantibodies with severe COVID-19 (11, 15, 17-19). Thus,

we sought to further characterize ANA-positive and ANA-negative COVID-19 patients during

acute disease by proteomics comprising 86 inflammatory markers, cytokine measurements,

flow cytometry, clinical history, and routine diagnostic analyses. The proportion of participants

with a known autoimmune disease was low in our cohort and indifferent in individuals with or

without ANA or ANCA (**Table 2**). We found a higher prevalence of comorbidities in

autoantibody-positive patients, including hypertension and heart disease, but no significant sex

difference (**Table 2**).

A multivariate analysis with 130 variables, including demographic parameters, routine

diagnostic measurements, and inflammation markers obtained by proteomics (**Table S6**),

allowed for a nearly complete separation of severe COVID-19 patients from healthy

individuals, with mild COVID-19 patients exhibiting intermediate characteristics (**Fig. 6A**).

Several markers contributing to severe COVID-19 were significantly higher ($p < 0.05$) in

ANA-positive than ANA-negative COVID-19 patients, revealing an inflammatory signature

associated with severe disease in ANA-positive individuals (**Fig. 6B**). Importantly, ANA-

positive COVID-19 patients were older and experienced longer hospitalization (**Fig. 6C**), and

many inflammation markers, including C-reactive protein (CRP) and interleukin (IL)-6, were

elevated compared to ANA-negative patients (**Fig. 6D**). Furthermore, ANA-positivity was

associated with T cell activation as suggested by higher soluble IL-2 receptor alpha (sIL-2Rα)

serum concentrations and increased proportions of activated $CD38^+$ $HLA\text{-}DR^+$ $CD4^+$ and $CD8^+$

T cells (**Fig. 6E**). Similar trends toward an inflammatory signature were also observed in

ANCA-positive individuals during acute COVID-19, although these results were limited due

to lower prevalence of ANCA (**Fig. S4A** and **B**).

Finally, we assessed characteristics of ANA-positive and ANA-negative COVID-19 patients

at six months after acute disease to identify alterations in the absence of acute inflammation. A

multivariate analysis of 43 parameters, including patient characteristics and routine diagnostic

measurements, revealed differences comparing ANA-positive and ANA-negative individuals

(**Fig. 6F, Table S7**), with several inflammation markers, including IL-6, tumor necrosis factor

alpha (TNF-α), and sIL-2Rα, being significantly higher in ANA-positive participants (**Fig. 6F**

and **G**, **Table S7**). Interestingly, we also observed differences in Ig subclasses, with

significantly higher IgG1 and significantly lower IgM in ANA-positive individuals (**Fig. 6H**).

Furthermore, marked changes in B cell subsets were apparent, with higher frequencies of IgD^+

$CD27^-$ naïve B cells and lower frequencies of IgD^+ $CD27^+$ non-switched and IgD^- $CD27^+$

switched memory B cells in ANA-positive individuals (**Fig. 6I**). Altogether, in autoantibody-

positive COVID-19 patients, we found an inflammatory signature during acute disease

resembling alterations found in severe disease and changes in inflammation markers, Ig

subclasses, and B cells at six months after recovery.

Discussion

Although autoantibodies targeting nuclear, cytoplasmic, and soluble autoantigens following viral infections have been well described (35, 36), their significance has remained ill-defined. In this study, we used highly sensitive assays to detect ANA and ANCA, representing systemic autoantibodies, in patients up to one year after infection with SARS-CoV-2. Firstly, we found transient ANA and ANCA in a subgroup of participants during acute COVID-19. Autoantibody production could result from activation of autoreactive B and T cells recognizing viral epitopes by means of molecular mimicry (37, 38). Alternatively, antigen-independent 'bystander' activation of autoreactive B and T cells by cytokines and other inflammatory mediators could drive autoantibody production (28, 39). Particularly in severe COVID-19, which is associated with early neutrophilia and pronounced neutrophil extracellular trap (NET) formation (40, 41), NETs expose shielded intracellular self-antigens (32, 42, 43), thus causing production of ANCA and ANA. Interestingly, a high prevalence of IgA ANCA has been reported in acute COVID-19 patients showing chilblain-like lesions (21). In our study, all ANCA-positive subjects tested negative for anti-MPO and anti-PR3 antibodies, thus it remains elusive whether these ANCA have pathogenic potential.

Secondly, we found distinct features in autoantibody-positive COVID-19 patients during acute disease and recovery. Autoantibodies were associated with prolonged hospitalization and inflammation markers during acute disease, supporting recent findings (11, 15, 17-19, 44, 45). Whereas autoantibodies targeting type I interferons have been linked to severe COVID-19 (10-12, 16), severe COVID-19 could decrease self-tolerance by tissue damage and inflammation, altogether leading to generation of autoantibodies. However, confounding factors should be considered, such as age and comorbidities, affecting prevalence of autoantibodies and risk of severe COVID-19. Following these considerations, we found changes in ANA-positive individuals even six months after acute COVID-19, indicating ongoing low-grade

inflammation. Furthermore, we observed alterations of the B cell compartment, including

increased naïve and decreased memory B cells, previously associated with pre-symptomatic

and early-stage autoimmune diseases (46-48). Differences in total Ig concentrations have been

found in autoimmune diseases (49) and patients suffering from post-acute COVID-19

syndrome (PACS) (50). Thus, we have previously identified an Ig signature in PACS, including

low total IgM, and found clinical risk factors, including increased age and severe disease course

(50). Although a direct link to autoantibody development in PACS has not been reported, a

misdirected immune response may underly both manifestations.

Thirdly, we observed higher S1-specific antibody titers in autoantibody-positive COVID-19

patients. Similarly, recent reports found increased anti-viral humoral responses in

autoantibody-positive individuals during acute COVID-19, although the interrelation remained

unclear (16, 19, 22). Interestingly, following COVID-19 mRNA vaccination in systemic lupus

erythematosus (SLE) patients, higher humoral responses positively correlated with anti-

dsDNA antibodies (45), supporting our findings of increased S1-specific IgA production in

ANA-positive individuals following vaccination. Human virome-wide serological profiling

revealed production of cross-reactive antibodies to other coronaviruses during acute COVID-

19, particularly in severe disease, consistent with broader humoral immune responses in severe

COVID-19 (34). Whereas antibodies targeted similar cross-reactive coronavirus epitopes in

ANA-positive and ANA-negative COVID-19 patients, more antibodies targeted EBV antigen

EBNA-2 in ANA-positive individuals. Higher humoral responses against EBV have been

described in ANA-positive individuals, irrespective of autoimmune disease (51, 52). Also,

EBV has been associated with development of ANA and SLE (53). Furthermore, severe acute

COVID-19 is characterized by extrafollicular B cell activation (20, 44, 54), which is found in

autoimmune disease and associated with activation of autoreactive B cells. This increased

response could allow for rapid formation of virus-specific antibody-secreting cells (20),

potentially explaining why individuals with autoantibodies exhibit higher humoral responses

during acute COVID-19. Whether autoantibody-positive subjects also show increased SARS-

CoV-2-specific long-lived T cells responses (55) remains to be investigated.

Limitations of this study include the use of highly sensitive IIF assays that yielded a high

prevalence of positive results in healthy subjects and COVID-19 patients. Most of the measured

ANA titers were at or just above the threshold level, which usually would be considered of

irrelevant clinical significance. Moreover, we did not assess the specificity of autoantibodies,

but recent studies have shown reactivity to a wide spectrum of autoantigens (11, 16).

Altogether, our study shows autoantibodies in COVID-19 appear to be transient and correlate

with increased anti-viral humoral immune responses and a distinct immune signature. As

questions arise regarding long-term consequences of COVID-19, including the risk of immune

dysregulation and autoimmune disease, understanding the mechanisms involved in balancing

self-tolerance and protective immune responses become crucial to recognize and manage

patients at risk for developing autoimmune diseases.

Acknowledgments

We thank the diagnostic laboratories of the University Hospital Zurich, Alessandra Guaita, Claudia Meloni, Jennifer Jörger, Jana Epprecht and Claudia Bachmann for their support, and the members of the Boyman Laboratory for helpful discussions. The study overview graphic was generated with BioRender.com.

Author contributions

P.T. contributed to patient recruitment and data collection, analysis and interpretation. C.C. contributed to patient recruitment, data collection and data interpretation. Y.Z., S.H., and S.A. contributed to patient recruitment and data collection. C.P., Z.T., and P.B. contributed to data collection. M.E.R. contributed to patient recruitment and clinical management. E.B., A.R., M.S.-H., L.C.H., and J.N. contributed to patient recruitment. E.P.-M. contributed to data analysis. O.B. conceived the project and interpreted the data. P.T. and O.B. wrote the manuscript. All authors edited and approved the final draft of the article.

References

1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708-20.
2. Petersen E, Koopmans M, Go U, Hamer DH, Petrosillo N, Castelli F, et al. Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. Lancet Infect Dis. 2020;20(9):e238-e44.
3. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020;324(8):782-93.
4. Liu Y, Sawalha AH, Lu Q. COVID-19 and autoimmune diseases. Curr Opin Rheumatol. 2021;33(2):155-62.
5. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. N Engl J Med. 2020;382(17):e38.
6. Toscano G, Palmerini F, Ravaglia S, Ruiz L, Invernizzi P, Cuzzoni MG, et al. Guillain-Barré Syndrome Associated with SARS-CoV-2. N Engl J Med. 2020;382(26):2574-6.
7. Consiglio CR, Cotugno N, Sardh F, Pou C, Amodio D, Rodriguez L, et al. The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19. Cell. 2020;183(4):968-81.e7.
8. Zuo Y, Estes SK, Ali RA, Gandhi AA, Yalavarthi S, Shi H, et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci Transl Med. 2020;12(570).
9. Hsu TY, D'Silva KM, Patel NJ, Fu X, Wallace ZS, Sparks JA. Incident systemic rheumatic disease following COVID-19. Lancet Rheumatol. 2021;3(6):e402-e4.
10. Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370(6515).
11. Wang EY, Mao T, Klein J, Dai Y, Huck JD, Jaycox JR, et al. Diverse functional autoantibodies in patients with COVID-19. Nature. 2021;595(7866):283-8.
12. Bastard P, Gervais A, Le Voyer T, Rosain J, Philippot Q, Manry J, et al. Autoantibodies neutralizing type I IFNs are present in. Sci Immunol. 2021;6(62).
13. Fujinami RS, von Herrath MG, Christen U, Whitton JL. Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease. Clin Microbiol Rev. 2006;19(1):80-94.
14. Vlachoyiannopoulos PG, Magira E, Alexopoulos H, Jahaj E, Theophilopoulou K, Kotanidou A, et al. Autoantibodies related to systemic autoimmune rheumatic diseases in severely ill patients with COVID-19. Ann Rheum Dis. 2020;79(12):1661-3.
15. Sacchi MC, Tamiazzo S, Stobbione P, Agatea L, De Gaspari P, Stecca A, et al. SARS-CoV-2 infection as a trigger of autoimmune response. Clin Transl Sci. 2021;14(3):898-907.
16. Chang SE, Feng A, Meng W, Apostolidis SA, Mack E, Artandi M, et al. New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat Commun. 2021;12(1):5417.
17. Pascolini S, Vannini A, Deleonardi G, Ciordinik M, Sensoli A, Carletti I, et al. COVID-19 and Immunological Dysregulation: Can Autoantibodies be Useful? Clin Transl Sci. 2021;14(2):502-8.
18. Chang SH, Minn D, Kim YK. Autoantibodies in moderate and critical cases of COVID-19. Clin Transl Sci. 2021.
19. Lerma LA, Chaudhary A, Bryan A, Morishima C, Wener MH, Fink SL. Prevalence of autoantibody responses in acute coronavirus disease 2019 (COVID-19). J Transl Autoimmun. 2020;3:100073.

20.   Woodruff MC, Ramonell RP, Saini AS, Haddad NS, Anam FA, Rudolph ME, et al.
Relaxed peripheral tolerance drives broad. medRxiv. 2021.
21.   Frumholtz L, Bouaziz JD, Battistella M, Hadjadj J, Chocron R, Bengoufa D, et al. Type
I interferon response and vascular alteration in chilblain-like lesions during the COVID-19
outbreak. Br J Dermatol. 2021.
22.   Emmenegger M, Kumar SS, Emmenegger V, Malinauskas T, Buettner T, Rose L, et al.
Anti-prothrombin autoantibodies enriched after infection with SARS-CoV-2 and influenced by
strength of antibody response against SARS-CoV-2 proteins. PLoS Pathog.
2021;17(12):e1010118.
23.   WHO. COVID-19 Clinical management: living guidance. World Health Organization
(2021), doi: www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1.
24.   Chan EK, Damoiseaux J, Carballo OG, Conrad K, de Melo Cruvinel W,
Francescantonio PL, et al. Report of the First International Consensus on Standardized
Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns 2014-2015. Front Immunol.
2015;6:412.
25.   Cervia C, Nilsson J, Zurbuchen Y, Valaperti A, Schreiner J, Wolfensberger A, et al.
Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe
COVID-19. J Allergy Clin Immunol. 2021;147(2):545-57.e9.
26.   Adamo S, Chevrier S, Cervia C, Zurbuchen Y, Raeber ME, Yang L, et al. Profound
dysregulation of T cell homeostasis and function in patients with severe COVID-19. Allergy.
2021;76(9):2866-81.
27.   Lundberg M, Eriksson A, Tran B, Assarsson E, Fredriksson S. Homogeneous antibody-
based proximity extension assays provide sensitive and specific detection of low-abundant
proteins in human blood. Nucleic Acids Res. 2011;39(15):e102.
28.   Chevrier S, Zurbuchen Y, Cervia C, Adamo S, Raeber ME, de Souza N, et al. A distinct
innate immune signature marks progression from mild to severe COVID-19. Cell Rep Med.
2021;2(1):100166.
29.   Pou C, Nkulikiyimfura D, Henckel E, Olin A, Lakshmikanth T, Mikes J, et al. The
repertoire of maternal anti-viral antibodies in human newborns. Nat Med. 2019;25(4):591-6.
30.   Mina MJ, Kula T, Leng Y, Li M, de Vries RD, Knip M, et al. Measles virus infection
diminishes preexisting antibodies that offer protection from other pathogens. Science.
2019;366(6465):599-606.
31.   Suwanchote S, Rachayon M, Rodsaward P, Wongpiyabovorn J, Deekajorndech T,
Wright HL, et al. Anti-neutrophil cytoplasmic antibodies and their clinical significance. Clin
Rheumatol. 2018;37(4):875-84.
32.   Nakazawa D, Kumar S, Desai J, Anders HJ. Neutrophil extracellular traps in tissue
pathology. Histol Histopathol. 2017;32(3):203-13.
33.   Xu GJ, Kula T, Xu Q, Li MZ, Vernon SD, Ndung'u T, et al. Viral immunology.
Comprehensive serological profiling of human populations using a synthetic human virome.
Science. 2015;348(6239):aaa0698.
34.   Shrock E, Fujimura E, Kula T, Timms RT, Lee IH, Leng Y, et al. Viral epitope profiling
of COVID-19 patients reveals cross-reactivity and correlates of severity. Science.
2020;370(6520).
35.   Hansen KE, Arnason J, Bridges AJ. Autoantibodies and common viral illnesses. Semin
Arthritis Rheum. 1998;27(5):263-71.
36.   Spohn G, Arenas-Ramirez N, Bouchaud G, Boyman O. Endogenous polyclonal anti-
IL-1 antibody responses potentiate IL-1 activity during pathogenic inflammation. J Allergy
Clin Immunol. 2017;139(6):1957-65.e3.

37.   Moody R, Wilson KL, Boer JC, Holien JK, Flanagan KL, Jaworowski A, et al.
Predicted B Cell Epitopes Highlight the Potential for COVID-19 to Drive Self-Reactive
Immunity. Frontiers in Bioinformatics. 2021;1(31).
38.   Angileri F, Legare S, Marino Gammazza A, Conway de Macario E, Jl Macario A,
Cappello F. Molecular mimicry may explain multi-organ damage in COVID-19. Autoimmun
Rev. 2020;19(8):102591.
39.   Fajgenbaum DC, June CH. Cytokine Storm. N Engl J Med. 2020;383(23):2255-73.
40.   Zuo Y, Yalavarthi S, Shi H, Gockman K, Zuo M, Madison JA, et al. Neutrophil
extracellular traps in COVID-19. JCI Insight. 2020;5(11).
41.   Reusch N, De Domenico E, Bonaguro L, Schulte-Schrepping J, Baßler K, Schultze JL,
et al. Neutrophils in COVID-19. Front Immunol. 2021;12:652470.
42.   van der Linden M, van den Hoogen LL, Westerlaken GHA, Fritsch-Stork RDE, van
Roon JAG, Radstake TRDJ, et al. Neutrophil extracellular trap release is associated with
antinuclear antibodies in systemic lupus erythematosus and anti-phospholipid syndrome.
Rheumatology (Oxford). 2018;57(7):1228-34.
43.   Egholm C, Heeb LEM, Impellizzieri D, Boyman O. The Regulatory Effects of
Interleukin-4 Receptor Signaling on Neutrophils in Type 2 Immune Responses. Front
Immunol. 2019;10:2507.
44.   Woodruff MC, Ramonell RP, Nguyen DC, Cashman KS, Saini AS, Haddad NS, et al.
Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in
COVID-19. Nat Immunol. 2020;21(12):1506-16.
45.   Izmirly PM, Kim MY, Samanovic M, Fernandez-Ruiz R, Ohana S, Deonaraine KK, et
al. Evaluation of Immune Response and Disease Status in SLE Patients Following SARS-CoV-
2 Vaccination. Arthritis Rheumatol. 2021.
46.   Baglaenko Y, Chang NH, Johnson SR, Hafiz W, Manion K, Ferri D, et al. The presence
of anti-nuclear antibodies alone is associated with changes in B cell activation and T follicular
helper cells similar to those in systemic autoimmune rheumatic disease. Arthritis Res Ther.
2018;20(1):264.
47.   Zhu L, Yin Z, Ju B, Zhang J, Wang Y, Lv X, et al. Altered frequencies of memory B
cells in new-onset systemic lupus erythematosus patients. Clin Rheumatol. 2018;37(1):205-12.
48.   Slight-Webb S, Lu R, Ritterhouse LL, Munroe ME, Maecker HT, Fathman CG, et al.
Autoantibody-Positive Healthy Individuals Display Unique Immune Profiles That May
Regulate Autoimmunity. Arthritis Rheumatol. 2016;68(10):2492-502.
49.   Zhang H, Li P, Wu D, Xu D, Hou Y, Wang Q, et al. Serum IgG subclasses in
autoimmune diseases. Medicine (Baltimore). 2015;94(2):e387.
50.   Cervia C, Zurbuchen Y, Taeschler P, Adamo S, Hasler S, Raeber M, et al.
Immunoglobulin signature predicts risk of post-acute COVID-19
syndrome   (2021).   Available   at   SSRN:
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3850036 . 2021.
51.   Slight-Webb S, Smith M, Bylinska A, Macwana S, Guthridge C, Lu R, et al.
Autoantibody-positive healthy individuals with lower lupus risk display a unique immune
endotype. J Allergy Clin Immunol. 2020;146(6):1419-33.
52.   Jog NR, Young KA, Munroe ME, Harmon MT, Guthridge JM, Kelly JA, et al.
Association of Epstein-Barr virus serological reactivation with transitioning to systemic lupus
erythematosus in at-risk individuals. Ann Rheum Dis. 2019;78(9):1235-41.
53.   Cuomo L, Cirone M, Di Gregorio AO, Vitillo M, Cattivelli M, Magliocca V, et al.
Elevated antinuclear antibodies and altered anti-Epstein-Barr virus immune responses. Virus
Res. 2015;195:95-9.

607 54. Kaneko N, Kuo HH, Boucau J, Farmer JR, Allard-Chamard H, Mahajan VS, et al. Loss
608 of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19. Cell.
609 2020;183(1):143-57.e13.
610 55. Adamo S, Michler J, Zurbuchen Y, Cervia C, Taeschler P, Raeber ME, et al. Signature
611 of long-lived memory CD8. Nature. 2021.
612

613   **Table 1. COVID-19 study cohort characteristics.**

		Healthy controls	COVID-19 Acute disease		COVID-19 6-month follow-up	
	Disease severity		**Mild**	**Severe**	**Mild**	**Severe**
	n (%)	41	109 (62.3%)	66 (37.7%)	77 (66.3%)	39 (33.7%)
Patient characteristics	**Age**	32 (28–52)	34 (28–52)	68 (57–78)	36 (29–53)	64 (58–74)
	Days after symptom onset		10 (7–16)	14 (9–27)	194 (185–205)	211 (194–224)
	Sex (female)	24 (58.5%)	54 (49.5%)	27 (40.9%)	40 (51.3%)	14 (35.9%)
	Vaccinated	0	0	0	9 (11.7%)	3 (7.7%)
	Hospitalized	–	20 (18.3%)	66 (100%)	12 (15.6%)	39 (100%)
Laboratory parameters	**Lymphocyte count (G/l)**	1.80 (1.48–2.33)	1.81 (1.18–2.23) ns	0.76 (0.56–1.10)****	1.96 (1.67–2.37) ns	1.77 (1.48–2.34) ns
	CRP (mg/l)	0.6 (0.4–1.6)	1.3 (0.6–5.3)**	59.2 (32.2–119.0)****	0.6 (0.6–1.3) ns	1.7 (2.2–5.1)**
	TNF-α (ng/l)	8.1 (6.4–10.0)	9.8 (7.6–12)**	16.4 (13.0–20.6)****	9 (6.8–10.9) ns	11.8 (9.3–15.0)****
	IL-6 (ng/l)	0.5 (0–1.1)	1.3 (0.1–4.9)***	19.5 (7.4–57.0)****	0.9 (0–2.1)*	1.6 (0.3–5.3)**
	S1-specific IgA (OD ratio)	0.33 (0.25–0.46)	1.77 (0.73–4.81)****	7.24 (2.52–10.2)****	2.52 (1.54–4.96)****	5.09 (3.12–7.75)****
	S1-specific IgG (OD ratio)	0.20 (0.17–0.25)	0.61 (0.27–2.19)****	5.12 (0.32–9.33)****	2.67 (1.29–5.69)****	6.91 (5.18–8.49)****
Comorbidities	**Hypertension (n)**	5 (12.2%)	12 (11.0%) ns	38 (57.8%)***	6 (7.8%) ns	21 (53.8%)**
	Diabetes (n)	2 (4.9%)	6 (5.5%) ns	19 (28.8%)*	4 (5.2%) ns	12 (30.7%)**
	Heart disease (n)	1 (2.4%)	6 (5.5%) ns	24 (36.6%)***	2 (2.6%) ns	15 (38.5%)***
	Lung disease (n)	5 (12.2%)	10 (9.2%) ns	12 (18.8%)*	5 (6.5%) ns	11 (28.2%) ns
	Malignancy (n)	1 (2.4%)	3 (2.8%) ns	8 (12.1%)**	3 (3.9%) ns	5 (12.8%) ns
	Kidney disease (n)	0 (0%)	8 (7.3%) ns	17 (25.8%)***	3 (3.9%) ns	10 (25.6%)**
	Autoimmune disease (n)	3 (7.3%)	6 (5.5%) ns	7 (10.6%) ns	6 (7.8%) ns	6 (15.4%) ns

614   Medians and interquartile ranges (in parentheses) are specified for continuous variables, with p-values obtained by Mann-Whitney U test, compared
615   to healthy individuals. Numbers of individuals (n) and percentages of corresponding subgroup (in parentheses) are shown for categorical variables,
616   with p-values calculated by Fisher's exact test, in comparison to healthy individuals. ns, non-significant; *, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$;
617   ****, $p < 0.0001$. OD, optical density.

Table 2. Characteristics of ANA- or ANCA-positive and -negative COVID-19 patients at acute disease or six months after infection.

		COVID-19 Acute disease			COVID-19 6-month follow-up		
ANA		**ANA-negative**	**ANA-positive**	**p-value**	**ANA-negative**	**ANA-positive**	**p-value**
Patient characteristics	**n (%)**	91 (52.0%)	84 (48.0%)	–	61 (52.6%)	55 (47.4%)	–
	Age	38 (30–58)	60.5 (38–73)	***	33 (29–47)	61 (45–69)	****
	Days after symptom onset	11 (7–16)	12 (7–19)	ns	195 (186–206)	204 (183–218)	ns
	Sex (female)	43 (47.3%)	38 (45.2%)	OR 0.92, ns	29 (47.5%)	25 (45.5%)	OR 0.95, ns
Comorbidities	**Hypertension**	18 (19.7%)	32 (38.1%)	OR 2.48, *	8 (12.1%)	19 (34.5%)	OR 3.39, **
	Diabetes mellitus	12 (13.2%)	13 (15.5%)	OR 1.20, ns	6 (9.8%)	10 (18.2%)	OR 1.99, ns
	Heart disease	9 (9.9%)	21 (25.0%)	OR 3.02, **	1 (1.6%)	16 (29.1%)	OR 23.68, ***
	Lung disease	15 (16.5%)	7 (8.3%)	OR 0.46, ns	9 (14.8%)	7 (12.7%)	OR 0.87, ns
	Kidney disease	11 (12.1%)	14 (16.7%)	OR 1.45, ns	2 (3.3%)	11 (20.0%)	OR 7.14, **
	Malignancy	4 (4.4%)	8 (9.5%)	OR 2.28, ns	4 (6.6%)	5 (9.1%)	OR 1.40, ns
	Autoimmune disease	8 (8.7%)	5 (5.9%)	OR 0.66, ns	5 (8.2%)	7 (12.7%)	OR 1.62, ns
ANCA		**ANCA-negative**	**ANCA-positive**	**p-value**	**ANCA-negative**	**ANCA-positive**	**p-value**
Patient characteristics	**n (%)**	158 (90.3%)	17 (9.7%)	–	113 (97.4%)	3 (2.6%)	–
	Age	44 (32–65)	71 (57–80)	***	43 (31–64)	69 (64–70)	–
	Days after symptom onset	11 (7–16)	11 (9–19)	ns	199 (187–216)	182 (164–212)	–
	Sex (female)	74 (46.8%)	7 (41.2%)	OR 0.79, ns	52 (46.0%)	1 (33.3%)	–
Comorbidities	**Hypertension**	41 (25.9%)	9 (52.4%)	OR 3.19, *	27 (23.9%)	0 (0%)	–
	Diabetes mellitus	21 (13.2%)	4 (23.5%)	OR 2.00, ns	15 (13.3%)	1 (33.3%)	–
	Heart disease	24 (15.2%)	6 (35.2%)	OR 3.02, ns	16 (14.2%)	1 (33.3%)	–
	Lung disease	21 (13.3%)	1 (5.9%)	OR 0.41, ns	15 (13.3%)	1 (33.3%)	–
	Kidney disease	22 (13.9%)	3 (17.6%)	OR 1.32, ns	12 (10.6%)	1 (33.3%)	–
	Malignancy	10 (5.9%)	2 (11.8%)	OR 1.96, ns	8 (7.1%)	1 (33.3%)	–
	Autoimmune disease	12 (7.6%)	1 (5.9%)	OR 0.76, ns	12 (10.6%)	1 (33.3%)	–

For continuous variables, medians and interquartile ranges (in parentheses) are specified, with p-values obtained by Mann-Whitney U test comparing individuals with and without autoantibodies. For categorical variables, numbers of individuals (n) and percentages of the corresponding subgroup (in parentheses) and odds ratios (OR) with p-values indicating significance in Fisher's exact test are shown. ns, non-significant; *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001.

Figure legends

Figure 1. Prevalence of autoantibodies in healthy controls and COVID-19 patients during acute disease and follow-up. (**A**) Study overview. (**B–I**) Prevalence of ANA titers (B-E) and ANCA (F-I) in healthy controls (n = 41) and COVID-19 patients during acute disease (n = 175), six months (n = 116) and one year (n = 92) after symptom onset. (**J–M**) Venn diagrams depicting co-occurrence of nuclear ANA, cytoplasmic ANA and ANCA in healthy individuals (J; n = 17), acute COVID-19 patients (K; n = 89) and COVID-19 patients six months (L; n = 56) or one year (M; n = 42) after SARS-CoV-2 infection that presented with at least one type of autoantibody. P-values indicate comparison of ANA (B-E) and ANCA (F-I) prevalence between mild and severe COVID-19 patients using Fisher's exact test.

Figure 2. IIF pattern of autoantibodies in acute and recovered COVID-19. (A–D)

Intersection plots showing counts of the four most prevalent ANA patterns (horizontal bars)

and counts of pattern combinations (vertical bars) as indicated by the dot matrix, for healthy

controls (A), and COVID-19 patients during acute disease (B), six months (C) and one year

after symptom onset (D). (**E–G**) Example IIF pictures showing the most common nuclear,

including fine-granular (E) and nucleolar (F), and cytoplasmic, including speckled (G), ANA

patterns observed in the study cohort. All images were recorded at a dilution of 1:320. (**H**) IIF

ANCA patterns observed in ANCA-positive COVID-19 patients during acute disease (n = 17)

and six months after recovery (n = 3). (**I**) Anti-MPO and anti-PR3 antibodies during acute

COVID-19 (n = 175) in ANCA-positive and ANCA-negative individuals. Dashed lines

indicate diagnostic cut-off values.

Figure 3. Paired longitudinal comparison indicates transient induction of autoantibodies in acute COVID-19. (**A–B**) Temporal trajectory of ANA titers, including all COVID-19 patients with at least one follow-up (n = 129), including six months (n = 116) or one year (n = 13) after symptom onset. Colors indicate development of ANA status from acute disease to follow-up. (**C**) Results from blinded, paired IIF picture analysis (n = 129). Patterns that were uniquely observed at one timepoint are colored. The p-value was obtained using Fisher's exact test comparing the prevalence of ANA-positive patients that presented with unique, transient patterns during acute disease or follow-up. (**D**) Exemplary IIF pictures of three patients exhibiting transient ANA patterns during acute COVID-19, with a transient nucleolar (left), cytoplasmic (middle), or mitotic (right) pattern. All pictures were recorded at a dilution of 1:320. (**E–F**) Temporal trajectory of ANCA titers (n = 129). Colors indicate development of ANCA status from acute disease to follow-up.

Figure 4. Presence of autoantibodies is associated with an increased virus-specific

humoral response after SARS-CoV-2 infection and vaccination. (**A–B**) S1-specific IgA and

IgG in ANA-positive and ANA-negative COVID-19 patients during acute disease (n = 175)

and six months after recovery (n = 104). (B) P-values indicate significance of the correlation

of ANA positivity as an independent parameter in a multiple linear regression model

accounting for age, disease severity and sampling timepoint (**Table S5**). (**C**) S1-specific IgA

and IgG in ANCA-positive and ANCA-negative COVID-19 patients during acute disease (n =

175). (**D**) ANA prevalence and titers in previously unexposed individuals (n = 11) before and

after vaccination with BNT162b2 at indicated timepoints. The p-value was calculated using

Chi-squared test of independence. (**E**) S1-specific IgA and IgG before and after COVID19

vaccination (n = 11). Red vertical lines indicate the timepoints of first and second vaccination

with BNT162b2. (**F**) S1-specific IgA and IgG in ANA-positive and ANA-negative participants

following COVID-19 vaccination with BNT162b2, combining data from 10-13d after the first

(n = 11) and 1-3d after the second (n = 10) vaccination.

Figure 5. Comprehensive serological profiling (VirScan) in ANA-positive and ANA-negative individuals during acute COVID-19. (**A**) Principal component analysis (PCA) accounting for summed epitope hits of 112 viral species, including data of 18 healthy individuals and 96 acute COVID-19 patients, grouped by timepoint of sample collection after symptom onset. Every dot represents an individual participant. Participant groups are encircled. (**B**) Loadings (variable coordinates) of the PCA depicted in (A), with each viral species shown as individual dot (**Table S4**). Colors indicate participant group with higher mean epitope hits per species. Viral species with a significant mean hits difference (p < 0.005) between COVID-19 patients and healthy controls are shown as large dots and annotated with colored font. Insignificantly differing coronaviruses (p > 0.005) are shown as crosses and annotated with black font. (**C**) Temporal association of summed epitope hits of six coronaviruses after symptom onset, shown for acute COVID-19 patients (n = 97) and healthy controls (n = 18). Horizontal bar represents mean of healthy controls. (**D**) Percentage of healthy controls and COVID-19 patients with positive results shown for epitopes of six coronavirus species with a prevalence up to 40%. Significantly enriched epitopes (p < 0.05) are colored and shaped according to the corresponding protein. (**E–F**) Summed hits for cross-reactive epitopes, comparing healthy controls and patients with mild and severe COVID-19 (E) or COVID-19 patients with or without ANA (F). (**G**) Percentage of ANA-positive and ANA-negative COVID-19 patients with positive results for cross-reactive and non-cross-reactive epitopes of six coronavirus species. Dashed lines mark the significance threshold at p < 0.05. (**H**) Percentage of ANA-positive and ANA-negative study participants (n = 115) with positive results, shown for all available epitopes. Epitopes with insignificant difference (p ≥ 0.005) are shown as grey dots, whereas significantly enriched epitopes (p < 0.005) are colored. EBV, Epstein-Barr virus; HSV-2, herpes simplex virus 2; VZV, varizella-zoster virus; other, other viruses comprising Aichivirus A and Mamastrovirus 1. (**I**) Summed epitope hits per individual

including all available epitopes, comparing ANA-negative and ANA-positive participants (top;

n = 115), and as a function of age (bottom).

Figure 6. ANA-positive COVID-19 patients exhibit a pro-inflammatory signature. (A)

PCA accounting for 130 parameters (**Table S6**) including data of healthy controls (n = 28) and

acute COVID-19 patients (n = 146). Participants with missing values were excluded from this

analysis. 95% confidence ellipses (t-distributed) are shown for healthy controls and severe

COVID-19 patients. (**B**) Loadings (variable coordinates) of the PCA depicted in (A), with each

parameter shown as an individual dot. Colors indicate the group of COVID-19 patients with

higher mean for each parameter, and parameters with significant differences ($p < 0.05$) are

represented as large dots and selected parameters are annotated (**Table S6**). (**C–E**) Comparison

of ANA-negative and -positive individuals among healthy controls or acute COVID-19

patients. (C) Patient characteristics, including duration of hospitalization (n = 174) and age (n

= 216). (D) Inflammation markers, including CRP (n = 209) and IL-6 (n = 215). (E) T cell

activation, including sIL-2Rα (n = 215), and $CD38^+HLA\text{-}DR^+$ $CD4^+$ (n = 210) and $CD8^+$ (n =

209) T cells. (**F–G**) PCA (F) and loadings (G) accounting for 43 parameters (**Table S7**)

including data of COVID-19 patients six months after recovery (n = 107). Participants with

missing values were excluded from this analysis. (**H–I**) Comparison of ANA-negative and

ANA-positive COVID-19 patients six months after recovery. (H) Concentration of total Ig

subclasses in serum (n = 116). (I) Frequency of B cell subsets, including IgD^+CD27^- naïve,

IgD^+CD27^+ non-switched memory and IgD^-CD27^+ switched memory B cells (n = 114).

Supplementary Figures

Figure S1. ANA patterns in healthy controls and COVID-19 patients during acute disease and follow-up. (**A–D**) Intersection plots showing the counts of all ANA patterns (horizontal bars) and counts of pattern combinations (vertical bars) as indicated by the dot matrix, as observed in healthy individuals (A; n = 41), acute COVID-19 patients (B; n = 175), and COVID-19 patients six months (C; n = 116) and one year (D; n = 92) after recovery.

Figure S2. S1-specific humoral response in ANA-positive and ANA-negative COVID-19 patients one year after recovery. S1-specific IgA and IgG in ANA-positive and ANA-negative COVID-19 patients (n = 37).

Figure S3. Human virome-wide serological profiling in healthy controls and acute COVID-19 patients. (**A**) Percentage of healthy controls (n = 18) and COVID-19 patients (n = 97) with positive results for all available epitopes of six coronavirus species. Significantly enriched epitopes ($p < 0.05$) are colored and shaped according to the corresponding protein. Dashed lines indicate significance threshold ($p < 0.05$). (**B**) Summed epitope hits of EBNA-2 and correlation with age in in ANA-negative and -positive participants (n = 115).

Figure S4. Multivariate characterization of ANCA-positive and ANCA-negative acute COVID-19 patients. (**A**) PCA accounting for 130 parameters including data of healthy controls (n = 28) and acute COVID-19 patients (n = 146). Participants with missing values were excluded from this analysis. (**B**) Loadings (variable coordinates) of the PCA depicted in (A), with each parameter shown as an individual dot (**Table S6**). Colors indicate participant

739   group with higher mean, and parameters with significant differences (p < 0.05) comparing

740   ANCA-positive and ANCA-negative COVID-19 patients are shown as large dots and

741   annotated.

A COVID-19 study cohort

Healthy individuals (n = 41)

COVID19 patients (n = 175)
Mild (n = 109) Severe (n = 66)

Acute (n = 175) → 6 months (n = 116) → 1 year (n = 92)

Clinical history & Sample collection

Flow cytometry & Immunoassays

Autoantibodies IIF (ANA, ANCA)

Proteomics (Olink) & Serological profiling (VirScan)

B Healthy controls
ANA titer
ANA-negative 1:640
1:320 >1:640
2 (5%)
5 (12%)
10 (24%)   24 (59%)

C Acute COVID-19
Total
15 (9%)
26 (15%)
43 (25%)   91 (52%)
Mild
8 (7%)
14 (13%)
24 (22%)   63 (58%)
Severe
7 (11%)
12 (18%)
19 (29%)   28 (42%)
p=0.061

D 6-month follow-up
Total
10 (9%)
22 (19%)
23 (20%)   61 (53%)
Mild
7 (9%)
7 (9%)
14 (18%)   49 (64%)
Severe
3 (8%)
15 (38%)
9 (23%)   12 (31%)
p=0.001

E 1-year follow-up
Total
6 (7%)
10 (11%)
23 (25%)   53 (58%)
Mild
4 (6%)
6 (9%)
14 (22%)   40 (62%)
Severe
2 (7%)
4 (14%)
9 (32%)   13 (46%)
p=0.17

F Healthy controls
ANCA status
ANCA-negative
ANCA-positive
1 (2%)
40 (98%)

G Acute COVID-19
Total
17 (10%)
158 (90%)
Mild
4 (4%)
105 (96%)
Severe
13 (20%)
53 (80%)
p=0.001

H 6-month follow-up
Total
3 (3%)
113 (97%)
Mild
1 (1%)
76 (99%)
Severe
2 (5%)
37 (95%)
p=0.26

I 1-year follow-up
Total
5 (5%)
87 (95%)
Mild
1 (2%)
63 (98%)
Severe
4 (14%)
24 (86%)
p=0.029

J Healthy controls
Nuclear ANA
14 (82%)
1 (6%) 0 (0%) 1 (6%)
1 (6%) 0 (0%) 0 (0%)
Cytoplasmic ANA   ANCA

K Acute COVID-19
Nuclear ANA
57 (64%)
9 (10%) 2 (2%) 10 (11%)
6 (7%) 0 (0%) 5 (6%)
Cytoplasmic ANA   ANCA

L 6-month follow-up
Nuclear ANA
43 (77%)
8 (14%) 1 (2%) 1 (2%)
2 (4%) 0 (0%) 1 (2%)
Cytoplasmic ANA   ANCA

M 1-year follow-up
Nuclear ANA
33 (79%)
3 (7%) 0 (0%) 2 (5%)
1 (2%) 0 (0%) 3 (7%)
Cytoplasmic ANA   ANCA

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6